Citral protects against metabolic endotoxemia, and systemic disorders caused by high-fat diet-induced obesity via intestinal modulation
Frontiers in Pharmacology · 07.04.2025 · 16
DOI: 10.3389/fphar.2025.1567217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.04.2025. Verfasst von Maycon Tavares Emílio-Silva und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Structural and Functional Biology, Physiology Sector, Institute of Bioscience, São Paulo State University (UNESP), Botucatu, Brazil. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa Do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Background
Obesity is a growing global epidemic associated with changes in the gut microenvironment and metabolic endotoxemia, which can exacerbate metabolic and inflammatory processes. Citral (CT), a monoterpene present in essential oils, has been investigated for its anti-inflammatory, antioxidant, and immunomodulatory properties. However, its role in modulating the gut axis during metabolic and inflammatory alterations in obesity remains unknown. In this study, we investigated the effects of CT on intestinal and metabolic impairment induced by lipopolysaccharide (LPS) and high-fat diet (HFD) in in vitro and in vivo models.
Methods
Male C57BL/6J mice were fed a standard diet and HFD for 17 weeks, with daily oral administration of CT treatment (25, 100, or 300 mg/kg) or vehicle. Morphological and histological parameters, lipid profiles, adipose index, cytokine levels, and colonic gene expression were determined. In vitro , murine rectal carcinoma (CMT-93) cells were stimulated with LPS (10 μg/mL) to assess tight junction and inflammatory protein expression.
Results
CT treatment showed anti-obesity activity against HFD-induced body mass gain in mice, which was attributed to a significant reduction in body fat, glycemia, and cholesterol levels. Systemic inflammation during obesity also decreased after CT treatment, with a significant reduction in serum levels of endotoxin, interleukin-1β, and tumor necrosis factor-α. Additionally, CT stimulation reduced inducible nitric oxide synthase expression and maintained ZO-1 levels in LPS-stimulated CMT-93 cells.
Conclusion
CT has anti-obesogenic, anti-inflammatory, and anti-hyperlipidemic properties mediated by its protective effects on the intestinal epithelium in obesity. Thus, our results highlight the promising preclinical results of CT treatment as a protective agent against the detrimental effects of HFD and LPS in mice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Structural and Functional Biology, Physiology Sector, Institute of Bioscience, São Paulo State University (UNESP), Botucatu, Brazil.
- Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.
- Department of Structural and Functional Biology, Morphology Sector, Institute of Bioscience, São Paulo State University, (UNESP), Botucatu, Brazil.
- CIBER de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Instituto de Salud Carlos III, Madrid, Spain.
Förderung
- Fundação de Amparo à Pesquisa Do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Emílio-Silva, M. T., Rodrigues, V. P., Fioravanti, M. M., Ruiz-Malagon, A. J., Naia Fioretto, M., Raimundo, P. R., Ohara, R., Assunção, R., Bueno, G., Dario, F. L., Justulin, L. A., Rodríguez-Nogales, A., da Rocha, L. R. M., Gálvez, J., & Hiruma-Lima, C. A. (2025). Citral protects against metabolic endotoxemia, and systemic disorders caused by high-fat diet-induced obesity via intestinal modulation. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1567217
Vancouver
Emílio-Silva MT, Rodrigues VP, Fioravanti MM, Ruiz-Malagon AJ, Naia Fioretto M, Raimundo PR, et al. Citral protects against metabolic endotoxemia, and systemic disorders caused by high-fat diet-induced obesity via intestinal modulation. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1567217
BibTeX
@article{EmlioSilva2025,
author = {Emílio-Silva, Maycon Tavares and Rodrigues, Vinicius Peixoto and Fioravanti, Mariana Moraes and Ruiz-Malagon, Antonio Jesús and Naia Fioretto, Matheus and Raimundo, Priscila Romano and Ohara, Rie and Assunção, Renata and Bueno, Gabriela and Dario, Felipe Lima and Justulin, Luis Antonio and Rodríguez-Nogales, Alba and da Rocha, Lucia Regina Machado and Gálvez, Júlio and Hiruma-Lima, Clélia Akiko},
title = {Citral protects against metabolic endotoxemia, and systemic disorders caused by high-fat diet-induced obesity via intestinal modulation},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1567217}
}
EUVIMED